This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price.
Shanyue Zeng, MA
Advertisement
Shanyue Zeng, MA, is a data scientist at IQVIA Market Access Technology Solutions.
ORCID ID: 0009-0008-0593-0473
Articles by Shanyue Zeng, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Hybrid, Outpatient, Network-Based: Bispecific Programs Take Shape Differently
2
Chemo-Free Options Abound for Transplant-Ineligible MCL, Kumar Explains
3
Defunding Co-Payment Assistance Disrupted nAMD Care
4
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
5